BIFIDO Co., Ltd. (KOSDAQ:238200)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,935.00
-35.00 (-1.18%)
At close: Apr 17, 2026
Market Cap24.01B -7.1%
Revenue (ttm)19.68B +59.3%
Net Income-192.74M
EPS-24.00
Shares Out8.18M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume21,033
Average Volume21,642
Open2,950.00
Previous Close2,970.00
Day's Range2,880.00 - 3,000.00
52-Week Range2,460.00 - 4,390.00
Beta1.00
RSI54.69
Earnings DateMay 14, 2026

About BIFIDO

BIFIDO Co., Ltd. produces probiotics-based products in South Korea and internationally. It offers bifidobacterium strain products, such as BGN4 for immune modulating; BORI used to treat rotavirus infection in infants; and AD011 for general intestinal health problems. The company was founded in 1999 and is headquartered in Hongcheon-eup, South Korea. [Read more]

Industry Pharmaceutical Preparations
Founded 1999
Employees 83
Stock Exchange KOSDAQ
Ticker Symbol 238200
Full Company Profile

Financial Performance

In 2025, BIFIDO's revenue was 19.68 billion, an increase of 59.34% compared to the previous year's 12.35 billion. Losses were -192.74 million, -96.43% less than in 2024.

Financial Statements